on Newron Pharmaceuticals S.p.A. (isin : IT0004147952)
Newron Pharmaceuticals Unveils H1 2025 Results and Strategic Advancements
Milan-based Newron Pharmaceuticals S.p.A. released its H1 2025 financial results and reported significant progress in its clinical programs. Notably, Newron secured regulatory approval for the ENIGMA-TRS Phase III trial, targeting treatment-resistant schizophrenia, with patient enrollment commencing in August 2025.
The company also expanded its strategic partnerships, signing a licensing agreement with Myung In Pharm for South Korea and strengthening ties with EA Pharma in Japan. This aligns with their strategy to enhance global reach and explore additional partnerships for evenamide's commercialization.
Financially, Newron recorded a noticeable improvement, with an increase in income and a reduction in net loss, coupled with a strong cash position, signaling robust health to support ongoing initiatives.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Newron Pharmaceuticals S.p.A. news